Abstract
Introduction: We previously reported our results of 98 Charnley Low-Friction Arthroplasty in 76 patients with Paget’s disease of the hip at an average follow-up of 10.4 years. The current report presents the outcome of this procedure at 15 to 30 years.
Methods: A total of 98 Charnley low-friction arthroplasties were performed on 76 patients, 27 men (37 hips) and 49 women (61 hips) with an average age of 67.4 years (range 51–79 years). All operations were performed by the trans-trochanteric or antero-lateral approach.
Results: When component revision was used as the endpoint, the survivorship of the acetabular component was 93% at 15 years (CI, 81% to 98%), 83% at 20 years (CI, 59% to 93%), 72% at 25 years (CI, 41% to 89%) and 36% at 30 years (CI, 2% to 78%). The survival of the femoral component was 91% at 15 years (CI, 80% to 96%), 84% at 20 years (CI, 60% to 94%), 84% at 25 years (CI, 60% to 94%) and 72% at 30 years (CI, 38% to 89%). The survival of both components was 89% at 15 years (CI, 76% to 95%), 81% at 20 years (CI, 56% to 92%), 81% at 25 years (CI, 56% to 92%) and 81% at 30 years (CI, 56% to 92%).
When component failure was used as the endpoint, the survivorship of the acetabular component was 78% at 15 years (CI, 64% to 87%), 66% at 20 years (CI, 48% to 80%), 43% at 25 years (CI, 21% to 62%) and 12% at 30 years (CI, 2% to 32%). The survival of the femoral component was 76% at 15 years (CI, 62% to 85%), 67% at 20 years (CI, 48% to 80%), 47% at 25 years (CI, 25% to 67%) and 7% at 30 years (CI, 1% to 26%). The survival of both components was 74% at 15 years (CI, 59% to 83%), 64% at 20 years (CI, 44% to 78%), 43% at 25 years (CI, 20% to 64%) and 7% at 30 years (CI, 1% to 27%).
Discussion and Conclusion: Long term results using Charnley’s Low Friction Arthroplasty achieved in this patient group are comparable to general arthroplasty population.
(Previous report: Charnley low-friction arthroplasty for Paget’s disease of the hip.
J Arthroplasty. 2000 Feb;15(2):210–9).
Correspondence should be addressed to Ms Larissa Welti, Scientific Secretary, EFORT Central Office, Technoparkstrasse 1, CH-8005 Zürich, Switzerland